🇺🇸 BNP7787 in United States

4 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Window: 22 April 2025 – 22 April 2026
Total reports: 4

Most-reported reactions

Diarrhoea — 1 report (25%)
Mental Status Changes — 1 report (25%)
Myocardial Ischaemia — 1 report (25%)
Pneumonia — 1 report (25%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is BNP7787 approved in United States?

BNP7787 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for BNP7787 in United States?

Alliance for Clinical Trials in Oncology is the originator. The local marketing authorisation holder may differ — check the official source linked above.